Newshub - NUS' News Portal

Cancer conference shares cutting-edge advances in cancer treatment and drug development

08 November 2010

SHARING A LIGHT-HEARTED MOMENT: (From left) Dean of the NUS Yong Loo Lin School of Medicine and Director of the National University Cancer Institute Prof John Wong; NUS Deputy President (Research and Technology) Prof Barry Halliwell; Permanent Secretary (National Research and Development) Mr Teo Ming Kian and Saw Swee Hock Centennial Professor in Medical Sciences and CSI Director Prof Daniel Tenen

KEYNOTE ADDRESS: Prof Stephen Quake delivering his talk on new technologies used in the understanding and diagnosis of cancer
The "Frontiers in Cancer Science" conference, which opened on 8 November 2010, brought together 30 top cancer experts from five countries who will share cutting-edge advances in cancer treatment and drug development over three days. The conference was co-organised by the Cancer Science Institute of Singapore (CSI), NUS together with the Duke-NUS Graduate Medical School Singapore, Genome Institute of Singapore and Institute of Molecular and Cell Biology of the Agency for Science, Technology and Research.

Speaking at the opening ceremony, Guest-of-Honour Permanent Secretary (National Research and Development) Mr Teo Ming Kian noted that "cancer is a challenging research area that requires concerted research effort". He felt that with the growing research shown in this field, the pharmaceutical industry would lead in delivering better cures and lower healthcare cost in a matter of time.

"What you do here in cancer research and what you do with the research output will make it happen - faster or slower. You can make a big difference to the patients waiting eagerly to be helped if you are successful. Not just pushing the frontiers in science to achieve breakthroughs but pushing these breakthroughs to the patients," said Mr Teo.

The conference will feature distinguished speakers such as Prof Stephen Quake, Lee Otterson Professor of Stanford University and Howard Hughes Medical Institute, who invented a technology that can sequence the entire genome for less than US$50,000. Participants from CSI include Assoc Prof Patrick Tan, Senior Principal Investigator and Programme Leader who focuses on the use of genomics to deliver personalised therapies for gastric cancer and Assoc Prof Chng Wee Joo, Senior Principal Investigator, who works on leukaemia.